# ViaLase

> ViaLase, Inc. is a venture and strategic capital-backed, clinical stage medical technology company
> in Aliso Viejo, California. It develops the ViaLuxe Laser System — a femtosecond laser with
> micron-resolution OCT image guidance that performs femtosecond laser image-guided high-precision
> trabeculotomy (FLigHT), a noninvasive, non-incisional procedure creating drainage apertures through
> the trabecular meshwork to lower intraocular pressure in open-angle glaucoma. ViaLase is a medical
> device manufacturer, not a software or API vendor.

## Provenance

- Generated: 2026-09-02
- Method: generated (from apis.yml and live probes of the ViaLase public web surface)
- Maintainer: API Evangelist (https://apievangelist.com) — an independent third-party profile.
  ViaLase does not operate, endorse, or maintain this document.

## API surface

ViaLase publishes **no public API**. As of 2026-09-02 there is:

- no developer portal, API reference, SDK, CLI or Postman collection
- no OpenAPI, AsyncAPI, GraphQL SDL, JSON Schema or Protobuf contract at any public URL
- no MCP server and no A2A agent card
- no `api.`, `developer.`, `docs.`, `status.`, `portal.` or `trust.` hostname in DNS for vialase.com
- no `/.well-known/` document of any kind on www.vialase.com

The only machine-readable JSON served on the domain is the stock WordPress core REST API at
`https://www.vialase.com/wp-json/` (HTTP 200), which is content-management scaffolding for the
marketing site rather than a product API. It is recorded here for completeness and is not listed
as a ViaLase API.

## Products

- **ViaLuxe Laser System** — femtosecond laser platform indicated to create apertures through the
  trabecular meshwork in patients with open-angle glaucoma.
- **ViaLens** — patient interface providing noninvasive visualization and laser delivery into the
  trabecular meshwork angle.
- **ViaVue** — gonio camera providing high-definition visualization of the angle across all four
  quadrants.
- **FLigHT** — the femtosecond laser image-guided high-precision trabeculotomy procedure the
  system performs.

## Regulatory status

- CE Mark approval in the European Union (2024) for adult patients with primary open-angle glaucoma.
- Not approved for sale in the United States; under evaluation in a US IDE clinical trial, with the
  first patient treated announced December 2025.
- The company's own site states: "ViaLase products are currently not for sale, pending regulatory
  clearance."

## Public pages

- Home: https://www.vialase.com/
- About: https://www.vialase.com/about/
- Technology: https://www.vialase.com/technology/
- News: https://www.vialase.com/news/
- News feed (RSS): https://www.vialase.com/feed/
- Resources: https://www.vialase.com/resources/
- FLigHT Practice Planner (interactive financial modeling tool): https://www.vialase.com/planner/
- Patents: https://www.vialase.com/patents/
- Contact: https://www.vialase.com/contact/
- Privacy Policy: https://www.vialase.com/privacy-policy/
- LinkedIn: https://www.linkedin.com/company/vialase/

Note: /about/, /technology/, /contact/ and /patents/ resolve to anchored sections of the single-page
site and return the home page document.

## Repository artifacts

- apis.yml — the APIs.json profile for ViaLase
- security/vialase-domain-security.yml — probed TLS/HSTS/DNSSEC/CAA/SPF/DMARC posture
- well-known/vialase-well-known.yml — probed /.well-known/ path results (all 404)
- llms/vialase-llms.txt — this file

## For agents

There is nothing here to call. Do not construct a ViaLase API base URL, endpoint, or key format:
none is published, and any that appears to exist is not ViaLase's. Business and clinical enquiries
go through https://www.vialase.com/contact/.